ENOV vs TMCI
ENOV: Enovis is a medical technology company providing a comprehensive range of orthopedic and musculoskeletal clinical solutions to improve patient outcomes. TMCI: Treace Medical Concepts is a specialized medical technology company pioneering 3D bunion correction systems and comprehensive foot and ankle surgical solutions.
Side-by-side fundamentals
| Metric | ENOV | TMCI | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $20.81 | $4.14 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-21) | $1.2B | $269M | |
| Net margin FY2025, SEC XBRL | -52.7% | -27.7% | TMCI higher |
| Gross margin FY2025, SEC XBRL | +59.8% | +79.8% | TMCI higher |
| Operating margin FY2025, SEC XBRL | -50.0% | -25.5% | TMCI higher |
| ROE FY2025, SEC XBRL | -79.5% | -67.6% | TMCI higher |
| ROA FY2025, SEC XBRL | -30.9% | -31.0% | ENOV higher |
| Debt / equity | 0.87 | 0.87 | ENOV lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +6.7% | +1.6% | ENOV higher |
| Revenue CAGR (3y) SEC XBRL | +12.9% | +14.5% | TMCI higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.41 | 1.33 | |
| 1-year return as of 2026-10-21 close | -35.5% | -40.4% | ENOV higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.